Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
November 05, 2026
November 05, 2026
NEW BRUNSWICK, New Jersey, Nov. 5 [Category: BizHealth & Beauty] -- Johnson and Johnson posted the following news release:
* * *
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
*
New Brunswick, N.J. (November 5, 2026) - Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administr . . .
* * *
Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO(tm) (amivantamab and hyaluronidase-lpuj) as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
*
New Brunswick, N.J. (November 5, 2026) - Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administr . . .
